Effect of ABO blood group on postoperative overall survival and recurrence-free survival rate in patients with hepatocellular carcinoma after hepatectomy: a multi-center retrospective cohort study
Hepatocellular carcinoma (HCC) is one of the most common malignancies worldwide. The survival rate after hepatectomy as the first line of treatment for HCC depends on various factors. This study evaluated the association of the ABO blood group and Rh with overall survival (OS) and Recurrence-free survival (RFS) rate after hepatectomy.
Methods
This multicenter retrospective cohort study reviewed the medical files of 639 HCC patients who underwent hepatectomy from 2010 to 2022 in three medical centers affiliated with the Iran University of Medical Sciences. Patient data, including demographic, clinical, tumor characteristics, and post-surgery outcomes, were collected by referring to the patient’s medical profiles. The Cox proportional hazard investigated the relationship between ABO blood group type and OS and RFS rate after hepatectomy.
Results
The five-year OS and RFS rates were 25.4% and 18.7%, respectively. The five-year OS (Lok rank:40.89, P:0.001) and RFS rate in patients with blood type A were significantly lower than in non-A patients. (Lok rank:10.8, P:0.001) The multivariate Cox analysis showed that blood type A, age < 45 years, tumor size > 5 cm, Poor tumor differentiation, presence of metastasis, The number of involved lymph nodes ≤ 2, and serum Alpha-Fetoprotein)AFP( level ≥ 400 were significantly related to the decreased survival rate of HCC patients after hepatectomy (P < 0.05) There was no significant association between Rh with OS and RFS (P > 0.05).
Conclusion
Blood group type A, compared to non-A, can be associated with decreased OS and RFS rates in patients with HCC after hepatectomy.
Hinweise
Maryam Najafirashed and Mansour Bahardoust are equal to the first authors.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Abkürzungen
HCC
Hepatocellular carcinoma
OS
Overall survival
RFS
Recurrence-free survival
AFP
Alpha-Fetoprotein
BMI
Body mass index
TNM
Tumor-node-metastasis index
HR
Hazard Ratio
95% CI
95% Confidence interval
Introduction
Hepatocellular carcinoma (HCC) is one of the most common malignancies worldwide. According to the International Agency for Research on Cancer (IARC), it is estimated that the annual number of new cases and deaths from liver cancer by 2040 will be more than 55% increase [1]. The prevalence of HCC is increasing in Asian and African countries and Western countries [2, 3].
HCC is one of the most important and intensifying global health challenges, especially in developing countries [4]. HCC is more common in men than women [5]. Hepatitis B is the most common cause of HCC [5, 6]. HCC, With a 5-year survival rate of 18%, is the third leading cause of cancer death worldwide, indicating the high lethality of this cancer [3, 7]. According to various studies, the 5-year recurrence rate of HCC has been reported between 4.9% and 39.9% [8], indicating that treating this cancer requires a multidisciplinary approach [8].
Anzeige
Hepatectomy, as the first line of treatment for HCC in patients with preserved liver function, is the best treatment method compared to local ablation and chemoembolization [9‐12]. However, the survival rate of these patients is still short and unsatisfactory due to the high recurrence of HCC after hepatectomy [13‐15]. The survival and recurrence rate of HCC after hepatectomy depends on factors such as tumor stage, maximum tumor diameter, degree of tumor differentiation and, GGT levels [16], histological grade of metastasis, age of patients, body mass index, and alpha-fetoprotein (AFP) levels [17‐22].
Recent studies have shown the relationship between the ABO blood group type and the survival rate of some cancers [23‐25]. Many studies reported that the ABO blood group type is associated with HCC survival after hepatectomy [22, 26]. While A. Oral et al., did not report a significant relationship between the type of blood group with the survival rate of HCC after hepatectomy [27]. The distribution of blood groups in different countries is different [28].
Based on our knowledge, limited studies have investigated the association of blood group type with overall survival and recurrence-free survival rate of HCC patients after hepatectomy. Considering the subject’s importance [26, 27], this retrospective cohort study aimed to evaluate the effect of the ABO blood group and RH factor on OS and RFS rates after Hepatectomy.
Methods
Patient characteristics
The Iran University of Medical Sciences ethics committee approved the present study with the code(IR.IUMS.REC.1401.925). In this multicenter retrospective cohort study, the medical profiles of 956 patients with HCC who underwent hepatectomy between 2010 and 2022 in hospitals affiliated with Iran Medical Sciences were reviewed. Six hundred forty-one patients were included. The definitive diagnosis of HCC was made based on pathology and biopsy findings and with an oncologist’s opinion.
Anzeige
Inclusion criteria included patients with a definite diagnosis of HCC and follow-up of at least six months after surgery. Secondary HCC (cases that did not originate from the liver), incomplete patient records, simultaneous suffering from other cancers, and lack of access to the blood bank were defined as the exclusion criterion.
Data collection
Patient data were collected using a three-part checklist, including demographic information, clinical and laboratory findings, tumor characteristics, and post-surgery outcomes by the researcher by referring to the medical profiles. Demographic characteristics included age, sex, education level, Body mass index (BMI), family history of HCC, alcohol consumption, and smoking. The laboratory and clinical information of the patients (hepatitis, hepatitis type, ALP level (ng/ml), Child–Pugh stage, ABO blood group e, and RH factor were. Tumor characteristics included tumor size, number of lymph nodes, cancer stage, tumor differentiation, and metastasis, which were collected by referring to the pathological findings of the patients. The outcomes investigated in this study included the duration of the follow-up, the median survival, the five-year OS, and the RFS rates based on the type of blood group.
Tumor characteristics were classified according to the AJCC 7th Edition Staging System for HCC guidelines [29]. Tumor-node-metastasis index (TNM) classification in this study includes tumor size (< 5 cm/ > 5 cm), number of involved lymph nodes (< 2 and ≥ 2), and presence of metastasis (positive/negative). Survival was defined as the time interval between hepatectomy and death.
Statistical analysis
Stata 17 and SPSS version 22 software were used for data analysis. Mean ± standard deviation was used to report quantitative variables. Qualitative variables were reported with frequency and (%). Kaplan–Meier was used to estimate patients’ OS and RFS rates after hepatectomy based on tumor characteristics and ABO blood group type. The significance of the Kaplan–Meier estimate for patient survival rate was reported using the Log Rank test. Univariate Cox proportional hazard ratio (HR) analysis was used to investigate the relationship between demographic, clinical, and tumor characteristics of OS and RFS rate after hepatectomy. Multivariate Cox regression analysis.
was used to control the effect of confounding variables. To estimate the adjusted effect of the ABO blood group type, the variables with P value < 0.2 [30] in univariate analysis were entered into the analysis of multivariate analysis with the backward method. The effect size with HR adjusted was reported in the 95% confidence interval (95% CI). A p-value less than 0.05 was considered a statistical significance level.
Results
Demographic and clinical characteristics
The mean age was 59.18 ± 11.38 years (range 25 to 86 years). The mean BMI was 22.7 ± 2.89 kg/m2. The majority of patients were married. The median survival was 32.5 (interquartile range (IQR): 27.4 to 37.6)months. The mean follow-up was 22.3 ± 56.7 months. The frequency of blood group types O, A, B, and AB was 219(34.2%), 201(31.4%), 148(23.1%), and 73(11.3%), respectively. Demographic and tumor characteristics were compared among four types of blood groups. Most of the patients in all four types of blood groups were 45 to 65 years old. (P: 0.65) The frequency of patients in stage I tumors was 15.4%, 18.3%, 18.2%, and 24.7% for blood groups A, O, B, and AB, respectively. (p:0.089) Nearly half of the patients in all blood groups had tumor size < 5 cm. (p: 16). The frequency of patients with serum AFP levels ≥ 400 ng/ml in patients with blood groups A, O, B, and AB was 33.8%, 34.2%, 33.8 and 14.6% respectively. (P: 0.095) There was no significant difference between the demographic, pathological findings, and tumor characteristics in patients with A and non-A blood groups (Table 1).
Table 1
Comparison of demographic and tumor characteristics based on the ABO blood group type
Demographic characteristics
N: 641 patients with HCC
ABO blood group type
ABO blood group type
O
(N:219)
A
(N:201)
B
(N:148)
AB
(N:73)
P value
A
(N:201)
Non-A
(N:440)
P value
Age group
0.65
0.54
• < 45 year
211 (32.9%)
69 (31.5%)
65 (32.3%)
54 (36.4%)
23 (29.5%)
65 (32.3%)
146 (33.2%)
• 45–65 year
312 (48.7%)
107 (48.9%)
104 (51.7%)
74 (50%)
33 (42.3%)
104 (51.7%)
208 (47.3%)
• > 65 year
118 (18.4%)
43 (19.6%)
32 (16%)
20 (13.6%)
22 (28.2%)
32 (16%)
86 (19.7%)
BMI (Kg/m2)
22.7 ± 2.89
22.9 ± 2.19
23.25 ± 3.11
21.54 ± 2.58
23.8 ± 2.55
0.44
23.25 ± 3.11
22.51 ± 3.09
0.41
Median survival (IQR 1, 3) Month)
32.5 (27.4, 37.6)
33.4 (28.5,38)
29.55 (24.7,34.3)
32.5 (28.1, 36.9)
32.8 (27.6, 37.8)
0.68
29.55 (24.7,34.3)
34.1 (29.4, 38.6)
0.54
Sex
0.88
0.75
• Male
486 (75.8%)
162 (74%)
159 (79.1%)
109 (73.6%)
56 (76.7%)
159 (79.1%)
327 (74. 3%)
• Female
155 (24.2%)
57 (26%)
42 (20.1%)
39 (26.4%)
22 (23.3%)
42 (20.1%)
113 (25.7%)
Smoking status
0.11
0.28
• Yes
277 (43.2%)
99 (45.2%)
90 (44.8%)
60 (40.5%)
28 (38.4%)
90 (44.8%)
187 (42.5%)
• NO
364 (56.8%)
120 (54.8%)
111 (55.2%)
88 (59.5%)
45 (61.6%)
111 (55.2%)
253 (57.5%)
Family history of GC
0.37
0.45
• Yes
58 (9%)
21 (9.6%)
17 (8.5%)
11 (7.4%)
9 (12.3%)
17 (8.5%)
41 9.3%)
• No
583 (91%)
198 (90.4%)
184 (91.5%)
137 (92.6%)
64 (87.7%)
184 (91.5%)
399 (90.7%)
Child–Pugh stage
0.22
0.28
• A
512 (79.9%)
178 (81.3%)
153 (76.1%)
118 (79.7%)
63 (86.4%)
153 (76.1%)
359 (81.6%)
• B
62 (9.7%)
25 (11.4%)
21 (10.5%)
11 (7.4%)
5 (6.8%)
21 (10.5%)
41 (9.3%)
• Unknown & missing
67 (10.4%)
16 (7.3%)
27 (13.4%)
19 (12.9%)
5 (6.8%)
27 (13.4%)
40 (9.1%)
Tumor size (cm)
0.16
0.19
• ≤ 5
317 (49.5%)
105 (47.9%)
93 (46.3%)
71 (48%)
43 (59%)
93 (46.3%)
224 (51%)
• > 5
236 (36.8%)
82 (37.4%)
79 (39.3%)
50 (33.8%)
25 (34.2%)
79 (39.3%)
157 (35.7%)
• Unknown & missing
88 (13.7%)
32 (14.7%)
29 (14.4%)
22 (18.2%)
5 (6.8%)
29 (14.4%)
59 (13.3%)
Metastasis
0.088
0.11
• Yes
328 (51.2%)
104 (47.5%)
100 (49.8%)
79 (53.4%)
43 (58.9%)
100 (49.8%)
228 (51.8%)
• No
110 (17.1%)
40 (18.2%)
36 (17.9%)
31 (20.9%)
5 (6.8%)
36 (17.9%)
74 16.8%)
• Unknown & missing
203 (31.7%)
75 (34.3%)
65 (32.3%)
38 (25.7%)
25 (34.3%)
65 (32.3%)
138 (31.4%)
Involved Lymph node
0.12
0.087
• < 2
325 (42.9%)
105 (48%)
86 (42.8%)
59 (39.9%)
25 (34.2%)
86 (42.8%)
239 (54.3%)
• ≥ 2
166 (25.9%)
49 (22.3%)
54 (26.8%)
39 (26.3%)
24 (32.9%)
54 (26.8%)
112 (25.5%)
• Unknown & missing
200 (31.2%)
65 (29.7%)
61 (30.4%)
50 (33.8%)
24 (32.9%)
61 (30.4%)
89 (20.2%)
Differentiation grade
0.054
0.049
• Well
114 (17.8%)
40 (18.2%)
30 (14.9%)
34 (23%)
10 (13.7%)
30 (14.9%)
84 (19.1%)
• Moderate
318 (49.6%)
110 (50.2%)
10 4 (51.7%)
69 (46.6%)
35 (47.9%)
104 (51.7%)
214 (48.6%)
• Poor
128 (20%)
42 (19.2%)
50 (24.9%)
28 (18.9%)
8 (11%)
50 (24.9%)
78 (17.79%)
• Unknown & missing
81 (12.6%)
27 (12.4%)
17 (8.5%)
17 (11.5%)
20 (27.4%)
17 (8.5%)
64 (14.6%)
Serum AFP level
0.095
0.068
• < 400 ng/ml
338 (52.7%)
111 (50.7%)
99 (49.3%)
80 (54.1%)
43 (58.9%)
99 (49.3%)
239 (54.3%)
• ≥ 400 ng/ml
205 (32%)
75 (34.2%)
68 (33.8%)
50 (33.8%)
12 (16.4%)
68 (33.8%)
137 (31.1%)
• Unknown & missing
98 (15.3%)
33 (15.1%)
34 (16.9%)
13 (12.1%)
18 (24.7%)
34 (16.9%)
65 (14.6%)
Cirrhosis
0.11
0.098
• Yes
258 (40.2%)
90 (41.1%)
85 (42.3%)
67 (45.3%)
16 (21.9%)
85 (42.3%)
173 9.3%)
• No
135 (21.1%)
48 (21.9%)
42 (20.9%)
28 (18.9%)
17 (23.3%)
42 (20.9%)
93 (21.1%)
• Unknown & missing
248 (38.7%)
81 (37%)
74 (36.8%)
53 (35.8%)
40 (54.8%)
74 (36.8%)
174 (39.6%)
Hepatitis type
0.084
0.14
• None
135 (21.1%)
42 (19.2%)
42 (20.9%)
32 (21.6%)
19 (26.1%)
42 (20.9%)
93 (21.1%)
• HBV
314 (49%)
96 (43.8%)
101 (50.2%)
76 (51.3%)
41 (56.2%)
101 (50.2%)
213 (48.4%)
• HCV
119 (18.6%)
50 (22.8%)
38 (18.9%)
28 (18.9%)
3 (4.1%)
38 (18.9%)
81 (18.4%)
• HBV + HCV
17 (2.7%)
5 (2.3%)
3 (1.5%)
2 (1.4%)
7 (9.5%)
3 (1.5%)
14 (3.2%)
• Unknown & missing
56 (8.6%)
26 (11.9%)
17 (8.5%)
10 (6.8%)
3 (4.1%)
17 (8.5%)
39 (8.9%)
RH
0.58
0.66
• +
570 (88.9%)
197 (90%)
176 (87.6%)
132 (90.2%)
65 (89%)
176 (87.6%)
394 (89.5%)
• -
71 (11.1%)
22 (10%)
25 (14.4%)
16 (10.8%)
8 (11%)
25 (14.4%)
46 (10.5%)
Five-year survival rate
The median OS and RFS time was 37 and 31 months, respectively. The five-year survival was 25.4%. The RFS rate was 18.7% (Fig. 1). The RFS rate for patients with blood groups A, O, B, and AB was 11.4%, 24.5%, 20.9%, and 19.9%, respectively. The highest and lowest 5-year survival rates were for patients with blood groups O and A, respectively. The OS rate for patients with blood groups A, O, B, and AB was 12.9%, 31.1%, 24.1, and 29.2%, respectively (Fig. 2). The OS rate in patients with blood type A was significantly lower than in non-A patients (12.9% vs. 29.7%). (Log rank: 40.89, P: 0.001) The five-year RFS rate in patients with blood group A was significantly lower than that of non-A blood groups (21.5% vs. 11.4%). (Log rank: 10.8, P: 0.001) (Fig. 3).
Fig. 1
Kaplan Meier of 1, 3, and five OS and RFS rate
Fig. 2
Kaplan–Meier of 5-year RFS and OS rate of patients based on blood type
Fig. 3
Kaplan-Meier of 5-year RFS and OS rate of patients based on blood type A versus non-A
×
×
×
Univariate analysis
Based on the results of univariate analysis, the survival rate in patients aged 45 to 65 years was significantly better than in patients < 45 years old. (HR: 0.66, 95% CI: 0.59, 0.73, P:0.001) The 5-year survival rate is significantly related to tumor size, AFP level, the number of involved lymph nodes, differentiation grade, tumor size, hepatitis, blood group type, and metastasis were related. There was no significant association between Rh with OS and RFS (P > 0.05) (P < 0.05) Table 2.
Table 2
Predictors of 5-year survival of patients with HCC based on univariate analysis
Demographic characteristics
Five-year survival rate
HR (95% CI)
P value
Age (year)
• < 45
21.2%
Ref
-
• 45–65
30.7%
0.66 (0.59,0.73)
0.001
• > 65
21.4%
0.99 (0.55, 2.84)
0.81
BMI (Kg/m2)
• ≤ 18
18.4%
Ref
-
• 18–25
29.8%
0.71 (0.60,0.83)
0.001
• > 25
23.2%
0.96 (0.71, 1.15)
0.087
Sex
0.25
• Male
24.9%
-
• Female
26.9%
Marital status
0.54
• Unmarried
27.2%
-
• Married
25.2%
Smoking status
0.61
• Yes
24.8%
-
• NO
26.1%
Education
• Illiterate
25.3%
-
0.81
• < Diploma
24.2%
• > = Diploma
26.1%
Family history of GC
0.12
• No
27.2%
• Yes
25.2%
Alcohol consumption
0.44
• No
26.6
• Yes
24.8
• Unknown & missing
25.4
Child–Pugh stage
0.12
• A
28.1
-
• B
24.7
• Unknown & missing
26.2
Tumor size (cm)
• ≤ 5
32.5%
Ref
-
• > 5
18.9%
1.73 (1.12,2.25)
0.001
• Unknown & missing
21.1%
1.48 (0.99,2.11)
0.074
Metastasis
• No
31.6%
Ref
-
• Yes
21.2%
1.52 (1.11, 1.93)
0.001
• Unknown & missing
23.8%
1.32 (1.06,1.6)
0.004
Involved Lymph node
• < 2
32.9%
Ref
-
• ≥ 2
20.11%
1.65 (1.16,2.17)
0.001
• Unknown & missing
24.6%
1.31 (1.04,1.62)
0.026
Differentiation grade
• Well
33.2%
Ref
-
• Moderate
24.3%
1.36 (1.08,1.65)
0.006
• Poor
17.2%
1.94 (1.44,2.46)
0.0001
• Unknown & missing
25.1%
1.30 (1.01,1.62)
0.043
Serum AFP level
• < 400 ng/ml
30.1%
Ref
-
• ≥ 400 ng/ml
20.4%
1.51 (1.12, 1.93)
0.0001
• Unknown & missing
25.6%
1.17 (0.96,1.43)
0.098
Cirrhosis
0.24
• Yes
26.6%
-
• No
24.7%
• Unknown & missing
25.3%
ABO Blood Type
• O
31.1%
Ref
-
• A
12.9%
2.41 (1.66,3.17)
0.001
• B
24.1%
1.29 (1.02,1.56)
0.045
• AB
29.2%
1.06 (0.86, 1.121)
0.18
ABO Blood Type
0.001
• Non-A
29.7%
Ref
• A
12.9%
2.3 (1.46,3.15)
Hepatitis type
• None
28.3%
Ref
-
• HBV
20.14%
1.41 (1.02,1.81)
0.008
• HCV
25.1%
1.13 (0.97, 1.3)
0.084
• HBV + HCV
19.1%
1.42 (0.98,1.89)
0.092
• Unknown & missing
22.4%
1.25 (0.92, 1.59)
0.11
Hepatitis type
0.013
• Non-HBV
26.3%
Ref
• HBV
20.14%
1.29 (1.04,1.55)
RH
-
0.88
• +
25.8%
• -
25.3%
Multivariate analysis
To determine the effect of blood group type on survival adjusted for other tumor and demographic characteristics, all variables that had p < 0.2 in the univariate analysis were entered into the Cox multivariate analysis adjusted by the backward method. The multivariate analysis showed that the blood types A, age < 45 years, tumor size > 5 cm, poor tumor differentiation, presence of metastasis, number of lymph nodes ≤ 2, and serum AFP level ≥ 400 were associated with decreased survival of patients after hepatectomy (P < 0.05) Table 3.
Table 3
Independent predictors for survival rate by multivariate analysis
Demographic characteristics
HR Adju
95% CI
P value
Age (< 45 vs > 45 year)
1.39
1.05, 1.74
< 0.001
BMI (Kg/m2)
• ≤ 18
1.26
1.07,1.45
< 0.001
• 18–25
Ref
-
-
• > 25
1.19
1.01, 1.37
0.017
Tumor size (≤ 5 vs > 5 cm)
1.65
1.09, 2.22
< 0.001
Metastasis ( Presence vs absence)
1.50
1.10, 1.91
0.006
Involved Lymph node (≥ 2 Vs < 2)
1.62
1.14,1.81
< 0.001
Differentiation grade
• Well
Ref
-
-
• Moderate
1.35
1.05,1.66
0.009
• Poor
1.90
1.41,2.39
< 0.0001
Serum AFP level (≥ 400 Vs < 400 ng/ml)
1.49
1.09,1.9
< 0.001
ABO Blood Type
• O
Ref
-
-
• A
1.69
1.21,2.18
< 0.001
• B
1.19
0.98,1.41
0.11
• AB
1.02
0.88, 1.17
0.25
ABO Blood Type (A Vs. Non A)
1.65
1.15,2.16
< 0.001
HR Adju Hazard Ratio adjusted, 95% CI 95% confidence interval
Discussion
Although many studies have investigated the association between the ABO blood group type and the risk of HCC, limited studies have investigated the association between the ABO blood group type and the survival rate of HCC patients after hepatectomy or liver transplantation. Based on our knowledge, no comprehensive study has investigated the association between ABO blood group type with survival and RFS rate in Iranian patients with HCC after hepatectomy. Therefore, according to the issue’s importance, in this retrospective cohort study, we evaluated the effect of ABO blood group type and Rh of patients with OS and RFS rate after hepatectomy in a multicenter manner in 639 HCC patients.
According to the results of our study, the five-year OS and RFS rates of patients were 25.4% and 18.7%, respectively, indicating the disease’s lethality even after surgery. The highest and lowest survival and RFS rates were related to blood groups O and A, respectively. The 5-year RFS and OS rate in patients with blood group O was 24.5% and 31.1%, respectively, and for blood group A was 11.4% and 12.9%, which indicated the lower survival of patients with blood group A. In line with the results of our study, in 2022, M Kaibori et al. [22] showed that 5-year RF and OS rates after hepatectomy were the lowest in patients with blood type A. In addition, the results of our study showed that patients with blood type O had higher 5-year OS and RFS rates after hepatectomy. Based on the results of multivariate analysis, the 5-year survival rate in patients with blood group A compared to non-A, patients < 45 years old compared to patients ≥ 45 years old, patients with tumor size > 5 cm compared to < 5 cm, poor differentiation, the presence of metastasis before surgery, the number of lymph nodes ≤ 2, and the serum AFP level ≥ 400 was significantly lower, which was consistent with the results of studies conducted in this field [26, 31, 32]. T Wu et al., [21] by evaluating the association ABO blood group type with the survival rate of HCC patients after hepatectomy in a retrospective cohort study on 691 patients, showed that the frequency of blood types A and O were 28.8% and 37.9%, respectively. In line with the results of their study, in our study, the frequency of blood types O and A was 34.1% and 31.3%, respectively. They reported that patients with blood type O had the highest survival and patients with blood type A had the lowest survival rate, with a median survival of 39 months, which was consistent with the results of our study. In their study, they reported that in addition to the type of blood groups, tumor size > 5 cm, higher tumor stage, presence of metastasis, age < 45 years, poor tumor differentiation, and serum AFP level ≥ 400 ng/ml were significantly associated with to the decrease in the survival rate of patients after hepatectomy. In our study, in addition to these factors, a BMI ≤ 18 kg/m2 was associated with a decrease in patient survival, which can be justified due to anorexia, weakness, and poor health status of underweight patients, weakening the immune system. Several previous studies showed that BMI ≤ 18 was associated with decreased survival rates for patients with gastric cancer after surgery. Therefore, post-surgery patients’ BMI can be considered an essential independent prognostic factor [33, 34].
In another study in 2022, K Mohkam et al. [32], by examining the effect of ABO blood group type on liver cancer recurrence after liver transplantation on 925 patients with HCC, showed that the 5-year survival and recurrence rate in patients with Blood type A was significantly higher than patients with non-A blood type, which was consistent with the results of our study. In another study, K Bannangkoon et al. [35] evaluated the effect of ABO blood group type on the survival of patients with HCC treated with embolization. They showed that the patients with blood type O compared to non-O had a significantly higher survival rate, confirming our study’s results. Similar to the results of our study, Q Li et al. [29] showed that in patients with inoperable HCC after transarterial chemoembolization (TACE), the survival rate of patients with blood type O was higher than that of non-O. Based on the results of previous studies, the increased risk of cancer and the lower survival rate of patients with type A blood can be justified due to the reduced ability of the immune system of patients with type A blood to identify and attack tumor cells expressing antigens that are structurally similar to ABO antigen [36, 37]. Contrary to the results of our study, A Oral et al., [27], by examining 502 cirrhotic patients with HCC, did not report a significant relationship between the ABO blood group with survival rate. This difference can be justified due to the difference in the characteristics of the patients under investigation and the difference in the sample size in the two studies. Their study examined only cirrhotic patients, while both cirrhotic and non-cirrhotic patients were examined in our study. Another strength of our study compared to this study was the larger sample size, conducting the study in a multicenter manner, and examining more factors adjusted for other factors.
Our study had limitations and strengths that should be noted. The retrospective study design was the most important weakness of our study, which made us unable to measure several important factors and tumor markers. In addition, due to the retrospective nature and the use of patients’ medical profiles, there were missing cases in a number of variables, which can affect the estimation of the results. The design of prospective studies with a large sample size is recommended to estimate the results more accurately. Designing a comprehensive multicenter study with a high sample size, for the first time on the Iranian population, to evaluate the effect of ABO blood group type on the survival rate of patients with HCC in conditions adjusted for other variables was one of the most important strengths of our study.
Anzeige
Conclusion
Our study showed that the blood group type as an independent factor was related to the five-year OS and RFS rate in patients with HCC after hepatectomy. Compared to non-A, blood type A can be associated with decreased five-year OS and RFS rates in patients with HCC after surgery. The five-year OS and RFS rates were higher in patients with blood type O than non-O. Prospective studies are recommended to estimate the results more accurately.
Acknowledgements
NA
Declarations
Ethics approval and consent to participate
This study was approved by the ethics committee of Iran University of medical science (IR.IUMS.REC.1401.925). All methods were carried out in accordance with relevant guidelines and regulations. The need for informed consent was waived by the Ethics Committee/Institutional Review Board of (Iran University of medical science).
Consent for publication
Not applicable.
Anzeige
Competing interests
The authors declare no competing interests.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Effect of ABO blood group on postoperative overall survival and recurrence-free survival rate in patients with hepatocellular carcinoma after hepatectomy: a multi-center retrospective cohort study
Nach PCI besteht ein erhöhtes Blutungsrisiko, wenn die Behandelten eine verminderte linksventrikuläre Ejektionsfraktion aufweisen. Das Risiko ist umso höher, je stärker die Pumpfunktion eingeschränkt ist.
In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.
Der Einsatz von Wundprotektoren bei offenen Eingriffen am unteren Gastrointestinaltrakt schützt vor Infektionen im Op.-Gebiet – und dient darüber hinaus der besseren Sicht. Das bestätigt mit großer Robustheit eine randomisierte Studie im Fachblatt JAMA Surgery.
Der belastende Arbeitsalltag wirkt sich negativ auf die psychische Gesundheit der Angehörigen ärztlicher Berufsgruppen aus. Chirurginnen und Chirurgen bilden da keine Ausnahme, im Gegenteil.
Update Chirurgie
Bestellen Sie unseren Fach-Newsletterund bleiben Sie gut informiert.
Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.
Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?
Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.
